13th November
Characterization of Demography and Comorbidity in Newly Diagnosed Multiple Myeloma Patients in the UK
Filipa Tunaru
Poster Session Time: 10:30 – 13:30
Discussion Period: 12:30 – 13:30
Using Bayesian Methodology to Minimize Control Recruitment in Trials of Relapsed and Refractory (RR) Multiple Myeloma (MM) Through Incorporation of Prior Control Response Information Borrowed From Real-World Evidence
Steven Soutar
Poster Session Time: 15:30 – 18:30
Discussion Period: 16:00 – 17:00
Treatment Pathways and Outcomes of Advanced Ovarian Cancer Patients Who Are Underrepresented in Trials
Dr Federica Picariello
Dr Lewis Carpenter
Poster Session Time: 10:30 – 13:30
Discussion Period: 12:30 – 13:30
Characterization of Time-to-Treatment-Discontinuation (TTTD) as a Proxy for Progression-Free Survival (PFS) in Real-World Evidence (RWE) Based Analyses of Relapsed-Refractory Multiple Myeloma (RRMM
Dr Joseph O’Reilly
Poster Session Time: 10:30 – 13:30
Discussion Period: 12:30 – 13:30